All participants received diet and exercise recommendations regardless of which treatment they were given
She added that some of the medications and dosages including oral semaglutide, dulaglutide, 0.6 mg liraglutide and 1 mg and 2 mg injectable semaglutide have not yet been approved by the FDA for the treatment of obesity and are more likely to have been prescribed for diabetes management. Perspective Back to Top A huge population was studied (413,000) that compared the effects of different weight loss medications
Patients who already qualify for GLP-1 therapy and would like additional support Individuals with suboptimal B12 levels or risk of deficiency Those who prefer combining metabolic and micronutrient therapy Patients fully committed to close medical oversight and follow-up However, its not recommended if you have contraindications to GLP-1 agents, are pregnant, breastfeeding, have uncontrolled GI disease, or cannot adhere to monitoring and follow-up
New Study Links Ozempic and Rare Eye Disease NAION The first study researching Ozempic and blindness looked at the medical records of more than 16,000 patients from 2017 to 2023 after Ozempic was released
Semaglutide (2.4 mg) caused nausea in 44.2% of participants in the STEP 1 trial, whereas vomiting and diarrhea were reported in 24.8% and 22.7%, respectively [18]
When drawing your dose, hold the syringe at eye level